<DOC>
	<DOCNO>NCT00796887</DOCNO>
	<brief_summary>The purpose study determine safety , tolerability , explore possible benefit extended-release niacin ( Niaspan® ) attempt improve recovery patient ischemic stroke .</brief_summary>
	<brief_title>Randomized , Controlled Trial Extended-Release Niacin ( Niaspan® ) Augment Subacute Ischemic Stroke Recovery</brief_title>
	<detailed_description>The investigator interested extended-release niacin ( Niaspan® ) potential restorative role ischemic stroke . At Henry Ford Hospital Detroit , Michigan , extended-release niacin ( Niaspan® ) show improve functional outcome rat administer first two week ischemic stroke onset . Such result encourage warrant investigation human . The specific aim study prospectively evaluate use extended-release niacin ( Niaspan® ) phase II clinical trial patient subacute ischemic stroke . The investigator assess safety tolerability Niaspan® evaluate outcome among treated patient 24 week ischemic stroke onset . This randomized , double-blinded , placebo-controlled , safety , tolerability , exploratory efficacy study extended-release niacin ( Niaspan® ) subacute ischemic stroke patient low HDL-C normal HDL-C cohort size 16 patient . A total enrollment 48 patient plan . Patients 72 hour 7 day stroke onset receive Niaspan® 500mg , 1000mg , placebo daily period 24 week . Evaluation potential safety tolerability subacute ischemic stroke patient make course treatment formal visit 6 , 12 , 24 week . The primary safety measure death , recurrent stroke , myocardial infarction , neurological worsening treatment . Exploratory analysis include functional outcome NIHSS score , modify Rankin score , Barthel indices 24 week . The goal study improve outcome ischemic stroke , use safe effective novel strategy restoration , translate basic laboratory study .</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Cerebral Infarction</mesh_term>
	<mesh_term>Niacin</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<mesh_term>Nicotinic Acids</mesh_term>
	<criteria>Patients clinical ischemic stroke able enroll 72 hour 7 day symptom onset . Patients age 1885 , inclusive . NIHSS score 421 , inclusive , prior treatment . Signed IRBapproved informed consent patient authorize representative . General Participation another study investigational drug device . Women know pregnant , lactating , childbearing potential positive urine betaHCG . Patients use niacin within 7 day previous stroke . Safety Related Unstable angina . Acute Myocardial infarction . Concurrent arterial bleeding . Active peptic ulcer disease . Platelet count le 100,000 per microliter . Internationally Normalized Ratio ( INR ) great 1.3 without use warfarin . Concurrent use bile acid sequestrants ( colestipol cholestyramine ) Baseline systolic blood pressure le 100 mmHg . History significant hepatic dysfunction . Allergy hypersensitivity aspirin . Concurrent use amiodarone , gemfibrozil , fibrate bile acid resin , cyclosporine , itraconazole , ketaconazole , telithromycin , erythromycin , clarithromycin , HIV protease inhibitor , nefazodone , danazol . Allergy hypersensitivity extendedrelease niacin . Allergy hypersensitivity statin agent . Potentially Interfering Outcomes Assessment Prior history dementia . Patients without fixed address deem unlikely present followup investigator . Patients whose life expectancy le 24 week . Prestroke modify Rankin score &gt; 2 . Glucose le 50 mg/dl . Other serious illness ( e.g. , severe hepatic , cardiac , renal failure ; complex disease may confound treatment assessment ) . Imaging Related Evidence primary intraparenchymal hemorrhage initial neuroimaging study . Neuroimaging evidence nonvascular cause neurological symptom .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Ischemic Stroke</keyword>
	<keyword>Recovery Function</keyword>
	<keyword>Extended-release niacin</keyword>
</DOC>